PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner.

MLA

Wu, Bogang, et al. “PPARγ Inhibition Boosts Efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a Sexually Dimorphic Manner.” International Journal of Biological Sciences, vol. 16, no. 9, Mar. 2020, pp. 1526–35. EBSCOhost, https://doi.org/10.7150/ijbs.42966.

APA

Wu, B., Sun, X., Yuan, B., Ge, F., Gupta, H. B., Chiang, H.-C., Li, J., Hu, Y., Curiel, T. J., & Li, R. (2020). PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. International Journal of Biological Sciences, 16(9), 1526–1535. https://doi.org/10.7150/ijbs.42966

Chicago

Wu, Bogang, Xiujie Sun, Bin Yuan, Fei Ge, Harshita B Gupta, Huai-Chin Chiang, Jingwei Li, Yanfen Hu, Tyler J Curiel, and Rong Li. 2020. “PPARγ Inhibition Boosts Efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a Sexually Dimorphic Manner.” International Journal of Biological Sciences 16 (9): 1526–35. doi:10.7150/ijbs.42966.